Fusion Antibodies (AIM:FAB) announced it has launched a redesigned, customer-focused website.
The Belfast-based contract research organisation provides antibody discovery, engineering and supply services for both therapeutic drug and diagnostic applications.
The company said the updated site presents its capabilities more clearly, making it easier for existing and prospective customers to understand its range of services and proprietary technologies, including its library-based discovery platforms.
Those platforms include the OptiMAL antibody library, which Fusion launched commercially in December following continued validation work with the U.S. National Cancer Institute, and which has since secured patent grants in Japan and Canada alongside acceptance in Australia.
The refresh follows a year in which Fusion reported FY2026 revenue of £2.1m, up from £1.97m, with gross margin improving to 53% from 22% and the operating loss narrowing to £1.13m from a restated £1.63m.